Evaluation of the association of CES1 (rs2244613) polymorphisms with the safety of remdesivir in hospitalized patients with COVID-19
I. I. Temirbulatov,
A. V. Kryukov,
K. B. Mirzaev,
N. P. Denisenko,
Sh. P. Abdullaev,
A. A. Kachanova,
Zh. A. Sozaeva,
A. S. Zhiryakova,
Yu. V. Shevchuk,
V. I. Vechorko,
O. V. Averkov,
D. A. Sychev https://doi.org/10.21518/2079-701X-2022-16-23-304-309
Abstract
Introduction. An outbreak of novel COVID-19 infection has become a real challenge for the entire human society, and first of all for the healthcare services. The development of new drugs is a complex and lengthy process. At the beginning of the pandemic, it forced an intensive study of well-known drugs for the therapy. Remdesivir was first investigated as a potential treatment for Ebola virus. After beginning of the COVID-19 pandemic, in vitro evaluations demonstrated its activity against SARS-CoV-2. Subsequent clinical studies showed the efficacy of remdesivir in shortening the time to recovery.
Aim. To evaluate the effect of the carriage of polymorphic alleles of the CES1 gene (A > C, rs2244613) on the safety profile of remdesivir therapy.
Materials and methods. A total of 154 patients hospitalized with coronavirus infection were included in the study. All patients received remdesivir as etiotropic therapy in the standard regimen: 200 mg on the first day followed by 100 mg daily for 5-10 days. In the course of observations, clinical and laboratory signs of adverse events were reported. Venous blood samples were collected from each patient for pharmacogenetic studies. Genotyping was performed using the real-time polymerase chain reaction technique. Statistical analysis: вata were analysed by using IBM SPSS Statistics, Version 23.0.
Results. There were no significant associations of carriage of various CES1 variants with the frequency of adverse reactions (bradycardia, nausea, vomiting) and laboratory markers of adverse events (ALT, AST, creatinine levels).
Conclusion. In our study, no association was found between the carriage of CES1 gene polymorphisms and the safety parameters of remdesivir in hospitalized patients with COVID-19. Further research into the possibilities of personalizing COVID-19 therapy through pharmacogenetic testing is needed.
Supporting agencies: This study was conducted with financial support from the Ministry of Health of the Russian Federation as part of the government assignment — Development of a Clinical Decision Support System for Adverse Drug Reaction Predictions in Patients with COVID-19 Based on Pharmacogenetic Testing (EGISU NIOKTR No. 122021800321-2).
About the Authors
I. I. Temirbulatov
Russian Medical Academy of Continuous Professional Education; City Clinical Hospital No. 15 named after О.М. Filatov
Russian Federation
Russian Federation
Ilyas I. Temirbulatov - Postgraduate Student of the Department of Clinical Pharmacology and Therapy named after Academician B.E. Votchal, Russian Medical Academy of Continuous Professional Education; Clinical Pharmacologist, City Clinical Hospital No. 15 named after О.М. Filatov.
2/1, Bldg. 1, Barrikadnaya St., Moscow, 125993; 23, Veshnyakovskaya St., Moscow, 111539
A. V. Kryukov
Russian Medical Academy of Continuous Professional Education; City Clinical Hospital No. 15 named after О.М. Filatov
Russian Federation
Russian Federation
Alexander V. Kryukov - Cand. Sci. (Med.), Associate Professor of the Department of Clinical Pharmacology and Therapy named after Academician B.E. Votchal, Russian Medical Academy of Continuous Professional Education; Clinical Pharmacologist, Head of the Department of Clinical Pharmacology, City Clinical Hospital No. 15 named after О.М. Filatov.
2/1, Bldg. 1, Barrikadnaya St., Moscow, 125993; 23, Veshnyakovskaya St., Moscow, 111539
K. B. Mirzaev
Russian Medical Academy of Continuous Professional Education
Russian Federation
Russian Federation
Karin B. Mirzaev - Dr. Sci. (Med.), Vice-Rector for Research and Innovation, Director of the Research Institute of Molecular and Personalized Medicine, Russian Medical Academy of Continuous Professional Education.
2/1, Bldg. 1, Barrikadnaya St., Moscow, 125993
N. P. Denisenko
Russian Medical Academy of Continuous Professional Education
Russian Federation
Russian Federation
Natalia P. Denisenko - Cand. Sci. (Med.), Deputy Director of the Research Institute of Molecular and Personalized Medicine, Associate Professor of the Department of Clinical Pharmacology and Therapy named after Academician B.E. Votchal, Russian Medical Academy of Continuous Professional Education.
2/1, Bldg. 1, Barrikadnaya St., Moscow, 125993
Sh. P. Abdullaev
Russian Medical Academy of Continuous Professional Education
Russian Federation
Russian Federation
Sherzod P. Abdullaev - Cand. Sci. (Bio.), Head of the Department of Predictive and Prognostic Biomarkers of the Research Institute of Molecular and Personalized Medicine, Russian Medical Academy of Continuous Professional Education.
2/1, Bldg. 1, Barrikadnaya St., Moscow, 125993
A. A. Kachanova
Russian Medical Academy of Continuous Professional Education
Russian Federation
Russian Federation
Anastasia A. Kachanova - Junior Researcher, Research Institute of Molecular and Personalized Medicine, Russian Medical Academy of Continuous Professional Education.
2/1, Bldg. 1, Barrikadnaya St., Moscow, 125993
Zh. A. Sozaeva
Russian Medical Academy of Continuous Professional Education
Russian Federation
Russian Federation
Zhannet A. Sozaeva - Junior Researcher, Research Institute of Molecular and Personalized Medicine, Russian Medical Academy of Continuous Professional Education.
2/1, Bldg. 1, Barrikadnaya St., Moscow, 125993
A. S. Zhiryakova
Russian Medical Academy of Continuous Professional Education
Russian Federation
Russian Federation
Anna S. Zhiryakova - Postgraduate Student of the Department of Clinical Pharmacology and Therapy named after Academican B.E. Votchal, Russian Medical Academy of Continuous Professional Education.
2/1, Bldg. 1, Barrikadnaya St., Moscow, 125993
Yu. V. Shevchuk
Russian Medical Academy of Continuous Professional Education
Russian Federation
Russian Federation
Yuliya V. Shevchuk - Postgraduate Student of the Department of Clinical Pharmacology and Therapy named after Academician B.E. Votchal, Russian Medical Academy of Continuous Professional Education.
2/1, Bldg. 1, Barrikadnaya St., Moscow, 125993
V. I. Vechorko
City Clinical Hospital No. 15 named after О.М. Filatov
Russian Federation
Russian Federation
Valery I. Vechorko - Dr. Sci. (Med.), Chief Physician, City Clinical Hospital No. 15 named after О.М. Filatov.
23, Veshnyakovskaya St., Moscow, 111539
O. V. Averkov
City Clinical Hospital No. 15 named after О.М. Filatov
Russian Federation
Russian Federation
Oleg V. Averkov - Dr. Sci. (Med.), Deputy Chief Physician, Head of Regional Vascular Center, City Clinical Hospital No. 15 named after О.М. Filatov.
23, Veshnyakovskaya St., Moscow, 111539
D. A. Sychev
Russian Medical Academy of Continuous Professional Education
Russian Federation
Russian Federation
Dmitry A. Sychev - Acad. RAS, Dr. Sci. (Med.), Professor, Rector, Head Department of the Clinical Pharmacology and Therapy named after Academician B.E. Votchal, Russian Medical Academy of Continuous Professional Education.
2/1, Bldg. 1, Barrikadnaya St., Moscow, 125993
References
1. Cui J., Li F., Shi Z. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17(3):181–192. https://doi.org/10.1038/S41579-018-0118-9.
2. Onyeaka H., Anumudu C.K., Al-Sharify Z.T., Egele-Godswill E., Mbaegbu P. COVID-19 pandemic: A review of the global lockdown and its far-reaching effects. Sci Prog. 2021;104(2):368504211019854. https://doi.org/10.1177/00368504211019854.
3. Khan M., Adil S.F., Alkhathlan H.Z., Tahir M.N., Saif S., Khan M. et al. COVID-19: A Global Challenge with Old History, Epidemiology and Progress So Far. Molecules. 2021;26(1):39. https://doi.org/10.3390/MOLECULES26010039.
4. Rehman S.U., Rehman S.U., Yoo H.H. COVID-19 challenges and its therapeutics. Biomed Pharmacother. 2021;142:112015. https://doi.org/10.1016/j.biopha.2021.112015.
5. Singh S.P., Pritam M., Pandey B., Yadav T.P. Microstructure, pathophysiology, and potential therapeutics of COVID-19: A comprehensive review. J Med Virol. 2021;93(1):275–299. https://doi.org/10.1002/jmv.26254.
6. Siegel D., Hui H.C., Doerffler E., Clarke M.O., Chun K., Zhang L. et al. Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f] [triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. J Med Chem. 2017;60(5):1648–1661. https://doi.org/10.1021/acs.jmedchem.6b01594.
7. Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271. https://doi.org/10.1038/s41422-020-0282-0.
8. Beigel J.H., Tomashek K.M., Dodd L.E., Mehta A.K., Zingman B.S., Kalil A.C. et al. Remdesivir for the Treatment of COVID-19 – Final Report. N Engl J Med. 2020;383(19):1813–1826. https://doi.org/10.1056/NEJMoa2007764.
9. Pan H., Peto R., Henao-Restrepo A.-M., Preziosi M.-P., Sathiyamoorthy V., Abdool Karim Q. et al. Repurposed Antiviral Drugs for COVID-19 – Interim WHO Solidarity Trial Results. N Engl J Med. 2021;384(6):497–511. https://doi.org/10.1056/NEJMoa2023184.
10. Lewis J.P., Horenstein R.B., Ryan K., O’Connell J.R., Gibson Q., Mitchell B.D. et al. The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. Pharmacogenet Genomics. 2013;23(1):1–8. https://doi.org/10.1097/FPC.0B013E32835AA8A2.
11. Li H., Zhang Z., Weng H., Qiu Y., Zubiaur P., Zhang Y. et al. Association between CES1 rs2244613 and the pharmacokinetics and safety of dabigatran: Meta-analysis and quantitative trait loci analysis. Front Cardiovasc Med. 2022;9. https://doi.org/10.3389/fcvm.2022.959916.
12. Elsawah H.K., Elsokary M.A., Abdallah M.S., ElShafie A.H. Efficacy and safety of remdesivir in hospitalized COVID-19 patients: Systematic review and meta-analysis including network meta-analysis. Rev Med Virol. 2021;31(4):e2187. https://doi.org/10.1002/RMV.2187.
13. Ader F., Bouscambert-Duchamp M., Hites M., Peiffer-Smadja N., Poissy J., Belhadi D. et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis. 2022;22(2):209–221. https://doi.org/10.1016/S1473-3099(21)00485-0.
14. Kalligeros M., Shehadeh F., Mylona E., Wands J.R., Mylonakis E. Poster Abstracts. Hepatology. 2021;74(Suppl. 1):157–1288. https://doi.org/10.1002/hep.32188.
15. Tuteja S., Yu Z., Wilson O., Chen H.C., Wendt F., Chung C.P. et al. Pharmacogenetic variants and risk of remdesivir-associated liver enzyme elevations in Million Veteran Program participants hospitalized with COVID-19. Clin Transl Sci. 2022;15(8):1880–1886. https://doi.org/10.1111/CTS.13313.
16. Aleem A., Mahadevaiah G., Shariff N., Kothadia J.P. Hepatic manifestations of COVID-19 and effect of remdesivir on liver function in patients with COVID-19 illness. Journal List. https://doi.org/10.1080/08998280.2021.1885289.
17. Sabers A.J., Williams A.L., Farley T.M. Use of remdesivir in the presence of elevated LFTs for the treatment of severe COVID-19 infection. BMJ Case Reports CP. 2020;13(10):e239210. https://doi.org/10.1136/BCR-2020-239210.
18. Zhai G., Li M., Wang Y., Wu J. Drug-Induced Liver Disturbance During the Treatment of COVID-19. Front Pharmacol. 2021;12:2149. https://doi.org/10.3389/FPHAR.2021.719308/BIBTEX.
19. Li Y., Cai H., Rajabalee N., Au X., Friedenberg F., Wallach S. S1027 Hepatotoxicity of Remdesivir for COVID-19: Systematic Review and Meta-Analysis. Am J Gastroenterol. 2020;115(1):523–523. https://doi.org/10.14309/01.AJG.0000706156.26271.8A.
20. Touafchia A., Bagheri H., Carrié D., Durrieu G., Sommet A., Chouchana L. et al. Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns. Clin Microbiol Infect. 2021;27(5):791.e5-791.e8. https://doi.org/10.1016/J.CMI.2021.02.013.
21. Attena E., Albani S., Maraolo A.E., Mollica M., de Rosa A., Pisapia R. et al. Remdesivir-Induced Bradycardia in COVID-19: A Single Center Prospective Study. Circ Arrhythm Electrophysiol. 2021;14(7):672–674. https://doi.org/10.1161/CIRCEP.121.009811.
22. Kumar S., Arcuri C., Chaudhuri S., Gupta R., Aseri M., Barve P. et al. Remdesivir therapy associated with Bradycardia in SARS-CoV2. Clin Cardiol. 2021;44(9):1190–1191. https://doi.org/10.1002/CLC.23700.
23. Gubitosa J.C., Kakar P., Gerula C., Nossa H., Finkel D., Wong K. et al. Marked Sinus Bradycardia Associated With Remdesivir in COVID-19: A Case and Literature Review. JACC Case Rep. 2020;2(14):2260–2264. https://doi.org/10.1016/J.JACCAS.2020.08.025.
24. Ching P.R., Lee C. Remdesivir-associated bradycardia. BMJ Case Rep. 2021;14(9):e245289. https://doi.org/10.1136/BCR-2021-245289.
25. Chow E.J., Maust B., Kazmier K.M., Stokes C. Sinus Bradycardia in a Pediatric Patient Treated With Remdesivir for Acute Coronavirus Disease 2019: A Case Report and a Review of the Literature. J Pediatric Infect Dis Soc. 2021;10(9):926–929. https://doi.org/10.1093/JPIDS/PIAB029.
26. Gérard A.O., Laurain A., Fresse A., Parassol N., Muzzone M., Rocher F. et al. Remdesivir and Acute Renal Failure: A Potential Safety Signal From Disproportionality Analysis of the WHO Safety Database. Clin Pharmacol Ther. 2021;109(4):1021–1024. https://doi.org/10.1002/cpt.2145.
27. Ertuğlu L.A., Kanbay A., Afşar B., Elsürer Afşar R., Kanbay M. COVID-19 and acute kidney injury. Tuberk Toraks. 2020;68(4):407–418. https://doi.org/10.5578/TT.70010.
28. Gérard A.O., Laurain A., Fresse A., Parassol N., Muzzone M., Rocher F. et al. Remdesivir and Acute Renal Failure: A Potential Safety Signal From Disproportionality Analysis of the WHO Safety Database. Clin Pharmacol Ther. 2021;109(4):1021–1024. https://doi.org/10.1002/CPT.2145.
29. Rezaee H., Pourkarim F., Pourtaghi-Anvarian S., Entezari-Maleki T., AsvadiKermani T., Nouri-Vaskeh M. Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview. Pharmacol Res Perspect. 2021;9(1):e00705. https://doi.org/10.1002/PRP2.705.
30. Zhang Q., Melchert P.W., Markowitz J.S. In vitro evaluation of the impact of COVID-19 therapeutic agents on the hydrolysis of the antiviral prodrug remdesivir. Chem Biol Interact. 2022;365:110097. https://doi.org/10.1016/J.CBI.2022.110097.
31. Shen Y., Eades W., Liu W., Yan B. The COVID-19 Oral Drug Molnupiravir Is a CES2 Substrate: Potential Drug-Drug Interactions and Impact of CES2 Genetic Polymorphism In Vitro. Drug Metab Dispos. 2022;50(9):1151–1160. https://doi.org/10.1124/dmd.122.000918.
Review
For citations:
Temirbulatov II, Kryukov AV, Mirzaev KB, Denisenko NP, Abdullaev SP, Kachanova AA, Sozaeva ZA, Zhiryakova AS, Shevchuk YV, Vechorko VI, Averkov OV, Sychev DA. Evaluation of the association of CES1 (rs2244613) polymorphisms with the safety of remdesivir in hospitalized patients with COVID-19. Meditsinskiy sovet = Medical Council. 2022;(23):304-309. (In Russ.) https://doi.org/10.21518/2079-701X-2022-16-23-304-309
Views:
564
Email this article 